Emmet B. Keeffe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Emmet B. Keeffe has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Mindie H. Nguyen
Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, 750 Welch Road, Suite 210, Palo Alto, CA 94304-1509, USA
16 shared publications - Aijaz Ahmed
Division of Gastroenterology and Hepatology Stanford University School of Medicine Stanford California USA
13 shared publications - Huy N. Trinh
Pacific Health Foundation
8 shared publications Ruel T. Garcia
8 shared publications- Gabriel Garcia
Stanford University Medical Center
7 shared publications - Huy A. Nguyen
San Jose Gastroenterology
7 shared publications
Latest Publications
- 30 September 2011
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 40 (3) , 495-505
Hepatitis B: Modern End Points of Treatment and the Specter of Viral Resistance
- 30 September 2011
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 40 (3) , 495-505
Hepatitis B: Modern End Points of Treatment and the Specter of Viral Resistance
- 6 August 2011
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (11) , 3106-3108
Access to Care and Optimal Treatment of Chronic Hepatitis B in Asian Americans: An Evolving Agenda
- 6 August 2011
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (11) , 3106-3108
Access to Care and Optimal Treatment of Chronic Hepatitis B in Asian Americans: An Evolving Agenda
- 1 June 2011
- Vol. 7 (6) , 366-73
IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection.
Genome-wide association studies have recently identified single nucleotide polymorphisms in proximity to the interleukin-28B (IL-28B) gene that can predict sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection who are undergoing therapy with pegylated interferon (IFN) a and ribavirin. IL-28B encodes IFN-λ3, a type III IFN involved in host antiviral immunity. Favorable variants of the 2 most widely studied IL-28B polymorphisms, rs1 2979860 and rs8099917, are strong pretreatment predictors of early viral clearance and SVR in patients with genotype 1 HCV infection. Variations in the distribution of IL-28B alleles may partly explain differences in SVR rates among ethnic groups. Further investigations have implicated IL-28B in the development of chronic HCV infection versus spontaneous resolution of acute infection and suggest that IL-28B may be a key factor involved in host immunity against HCV. Clinical trials of IFN-λ as a therapeutic agent for chronic HCV infection are currently underway. The use of IL-28B polymorphisms as a predictive tool will have a major impact on treatment strategies for chronic HCV infection, particularly in the context of emerging therapies and direct-acting antiviral agents.
- 1 June 2011
- Vol. 7 (6) , 366-73
IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection.
Genome-wide association studies have recently identified single nucleotide polymorphisms in proximity to the interleukin-28B (IL-28B) gene that can predict sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection who are undergoing therapy with pegylated interferon (IFN) a and ribavirin. IL-28B encodes IFN-λ3, a type III IFN involved in host antiviral immunity. Favorable variants of the 2 most widely studied IL-28B polymorphisms, rs1 2979860 and rs8099917, are strong pretreatment predictors of early viral clearance and SVR in patients with genotype 1 HCV infection. Variations in the distribution of IL-28B alleles may partly explain differences in SVR rates among ethnic groups. Further investigations have implicated IL-28B in the development of chronic HCV infection versus spontaneous resolution of acute infection and suggest that IL-28B may be a key factor involved in host immunity against HCV. Clinical trials of IFN-λ as a therapeutic agent for chronic HCV infection are currently underway. The use of IL-28B polymorphisms as a predictive tool will have a major impact on treatment strategies for chronic HCV infection, particularly in the context of emerging therapies and direct-acting antiviral agents.
- 1 June 2011
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (6) , 517-518
Risk score for development of HCC: ready for use in practice?
- 1 June 2011
- Published by Elsevier in The Lancet Oncology
- Vol. 12 (6) , 517-518
Risk score for development of HCC: ready for use in practice?
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
High Rate of Recurrent Hepatitis B Viremia Following Treatment-Induced Hepatitis B E Antigen (HBeAg) Seroconversion
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
High Rate of Recurrent Hepatitis B Viremia Following Treatment-Induced Hepatitis B E Antigen (HBeAg) Seroconversion
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Ethnic Differences in Etiology, Staging and Treatment Eligibility of Patients With Hepatocellular Carcinoma (HCC)
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Ethnic Differences in Etiology, Staging and Treatment Eligibility of Patients With Hepatocellular Carcinoma (HCC)